New drug combo shows promise for tough ovarian cancer
NCT ID NCT05296512
First seen Dec 18, 2025 · Last updated Apr 30, 2026 · Updated 26 times
Summary
This study tests whether combining two drugs, pembrolizumab and lenvatinib, can shrink tumors or slow cancer growth in people with recurrent clear cell ovarian cancer. About 30 participants who have already tried at least one other treatment will receive the drug combination. The main goals are to see how many respond and how long the cancer stays under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GYNECOLOGIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Mayo Clinic Comprehensive Cancer Center
Rochester, Minnesota, 55905, United States
-
University of Chicago Medicine
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.